Johnson & Johnson PAPILLON Data Sparks Valuation Debate

Johnson & Johnson has released final overall survival data from its Phase 3 PAPILLON trial, which showed that first-line RYBREVANT plus chemotherapy extended median survival in a hard-to-treat group of lung cancer patients.

The company's share price delivered a year-to-date return of 28.08%, but recent guidance updates and the PAPILLON data led to a decline of 3.51% over the past seven days, suggesting momentum has cooled in the short term.

Investors are divided on whether Johnson & Johnson is fully priced, with some pointing to the company's robust fundamentals and others warning that the stock's valuation is stretched.

According to analyst estimates, Johnson & Johnson's fair value stands at $270.59, suggesting a small valuation cushion that supports the current PAPILLON optimism.